OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2009
Business Overview: The company develops, manufactures, and markets oral fluid diagnostic products, specimen collection devices, and medical devices for cryosurgery. Key products include the OraQuick ADVANCE rapid HIV-1/2 antibody test and the Intercept drug testing system. The company operates primarily in the United States and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 28% in Q3 2009 compared to Q3 2008, driven by a 48% increase in OraQuick HIV test sales. For the nine-month period, revenues increased 4% year-over-year.
• Profitability Shift: The company reported a net income of $1.8 million in Q3 2009, reversing a net loss of $1.8 million in the same period in 2008. However, the nine-month period ended with a net loss of $5.0 million, compared to a $2.0 million loss in the prior year.
• Impairment Charge: A non-cash impairment charge of $3.0 million was recorded in Q2 2009 related to Hepatitis C (HCV) patent rights, negatively impacting the nine-month net loss.
• Operating Expenses: Research and development expenses decreased 30% in Q3 and 41% for the nine months ended September 30, 2009, primarily due to reduced clinical trial spending.
• Cash Flow: Net cash provided by operating activities improved significantly to $2.7 million for the nine months ended September 30, 2009, compared to a use of $3.7 million in the prior year period.

Guidance, Outlook, and Risks

• Manufacturing Resolution: The company resolved manufacturing issues with the OraQuick HIV test in Q3, resuming full-scale production and clearing a $2.2 million backlog.
• Regulatory Developments:
  • HCV Test: The FDA requires additional clinical testing for the OraQuick HCV test. The company expects these studies to be completed in the first half of 2010.
  • HIV OTC Test: The company plans to present a proposal for the OraQuick HIV OTC test to the FDA's Blood Products Advisory Committee in November 2009.
• Strategic Shifts: The company transitioned to a direct sales model for the U.S. hospital market in January 2009 following the termination of its distribution agreement with Abbott Laboratories.
• Risks and Contingencies:
  • Litigation: Pending patent infringement lawsuit filed by Inverness Medical Innovations and Church & Dwight regarding the OraQuick HIV test. A Markman hearing is expected in December 2009.
  • Economic Conditions: The economic downturn has negatively impacted substance abuse testing revenues (workplace testing) due to high unemployment.
  • Supply Chain: Reliance on sole-source providers for critical components, though arrangements have been made for HIV-1 antigen supply.

Investor Verification Checklist

• Backlog Clearance: Verify the sustainability of Q3 revenue growth now that the $2.2 million HIV test backlog has been fulfilled.
• HCV Regulatory Path: Monitor the timeline and cost implications of the additional FDA-mandated clinical trials for the HCV test.
• Litigation Outcome: Assess the potential financial impact of the Inverness Medical patent infringement lawsuit pending the Markman hearing.
• Substance Abuse Trends: Evaluate the correlation between U.S. unemployment rates and the company's Intercept drug testing revenue.
• Direct Sales Model: Confirm the long-term margin benefits of the direct sales model in the hospital market versus the previous distributor model.